Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Leucine Rich Bio is a South Asian precision medicine company specializing in microbiome data analysis and genomics. The company's flagship product, BugSpeaks, is a non-invasive gut microbiome test that utilizes proprietary shotgun metagenomics and bioinformatics to provide personalized nutritional and probiotic recommendations. Additionally, the company offers Rycher, a precision oncology platform designed to assist clinicians in identifying targeted therapies for cancer patients. By integrating advanced computational tools with biological data, Leucine Rich Bio aims to address complex health conditions such as gastrointestinal disorders, metabolic diseases, and cancer. The company operates primarily in the Indian and South Asian markets, providing diagnostic services to both consumers and healthcare providers.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Leucine Rich Bio.